TY - JOUR
T1 - Surgical resection for pulmonary recurrence of esophageal cancer after curative esophagectomy
AU - Morita, Masaru
AU - Yamamoto, Manabu
AU - Nakashima, Yuichiro
AU - Shiokawa, Keiichi
AU - Shin, Yuki
AU - Fujimoto, Yoshiaki
AU - Nakanoko, Tomonori
AU - Uehara, Hideo
AU - Sugiyama, Masahiko
AU - Ota, Mitsuhiko
AU - Mano, Yohei
AU - Sugimachi, Keishi
AU - Okamoto, Tatsuro
AU - Toh, Yasushi
N1 - Funding Information:
This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sport, Science and Technology of Japan (JSPS KAKENHI Grant number JP21K08766).
Publisher Copyright:
© 2021 The Author(s).
PY - 2021
Y1 - 2021
N2 - Aim: To clarify the significance of surgical resection for pulmonary recurrence after curative esophagectomy for esophageal cancer. Methods: Clinical details, such as the recurrence site, timing, and contents of therapies for recurrence, and the prognosis, were examined in 14 patients who underwent surgical resection for pulmonary recurrence that developed after curative esophagectomy. Results: The median disease-free interval after esophagectomy was 17.2 months. Two patients underwent pulmonary resection two times, and in one patient, three times. All pulmonary resections were performed when other extra-pulmonary recurrences had been controlled, and R0 resection was achieved. Chemotherapy and/or radiotherapy were additionally performed for pulmonary metastasis in 13 patients. The median survival time after initial pulmonary resection was 45.5 months, and the 1-, 3-, and 5-year overall survival rates were 93%, 68%, and 43%, respectively. The 5-year overall survival rate after initial pulmonary resection was 13% in patients with Stage III or IV esophageal cancer and 100% in those with Stage I or II disease (P = 0.010). The rate was 56% in patients with tumors < 20 mm in size, while all 5 patients with lesions ≥ 20 mm in size died within 3 years (P = 0.005). Conclusion: Surgical resection along with systemic therapy is a promising treatment strategy for pulmonary recurrence after curative esophagectomy when it is solitary and localized. Clinical factors, such as the esophageal cancer stage and the size of the pulmonary metastasis, are useful for deciding on the surgical indication.
AB - Aim: To clarify the significance of surgical resection for pulmonary recurrence after curative esophagectomy for esophageal cancer. Methods: Clinical details, such as the recurrence site, timing, and contents of therapies for recurrence, and the prognosis, were examined in 14 patients who underwent surgical resection for pulmonary recurrence that developed after curative esophagectomy. Results: The median disease-free interval after esophagectomy was 17.2 months. Two patients underwent pulmonary resection two times, and in one patient, three times. All pulmonary resections were performed when other extra-pulmonary recurrences had been controlled, and R0 resection was achieved. Chemotherapy and/or radiotherapy were additionally performed for pulmonary metastasis in 13 patients. The median survival time after initial pulmonary resection was 45.5 months, and the 1-, 3-, and 5-year overall survival rates were 93%, 68%, and 43%, respectively. The 5-year overall survival rate after initial pulmonary resection was 13% in patients with Stage III or IV esophageal cancer and 100% in those with Stage I or II disease (P = 0.010). The rate was 56% in patients with tumors < 20 mm in size, while all 5 patients with lesions ≥ 20 mm in size died within 3 years (P = 0.005). Conclusion: Surgical resection along with systemic therapy is a promising treatment strategy for pulmonary recurrence after curative esophagectomy when it is solitary and localized. Clinical factors, such as the esophageal cancer stage and the size of the pulmonary metastasis, are useful for deciding on the surgical indication.
UR - http://www.scopus.com/inward/record.url?scp=85114857945&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114857945&partnerID=8YFLogxK
U2 - 10.20517/2394-4722.2021.93
DO - 10.20517/2394-4722.2021.93
M3 - Article
AN - SCOPUS:85114857945
SN - 2394-4722
VL - 7
JO - Journal of Cancer Metastasis and Treatment
JF - Journal of Cancer Metastasis and Treatment
M1 - 30
ER -